Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celera Genomics (CRA) -- Ignore unavailable to you. Want to Upgrade?

To: John Lacelle who wrote (552)	7/10/2000 5:37:38 PM
From: John Solder	Read Replies (2) \| Respond to of 746

I think this whole human genome thing is blown way out of proportion. Even if you have the genetic sequence for a human gene, you are still a long way from having a "cure" for any disease for that might occur from a "defective" version. The sequence by itself is not the end, it's the beginning. Time will show this is a watershed in medical history, weather you want to believe it or not.

To: John Lacelle who wrote (552)	7/11/2000 3:44:23 AM
From: Walkingshadow	Read Replies (1) \| Respond to of 746

John, IMHO, there are many misconceptions and rampant misunderstanding of Celera, its direction, and its business model. In my view, Celera's future in no way depends upon selling genomic data per se. In fact, they will soon make the entire human genome public, by publishing it in conjuntion with the Human Genome Project, and probably also by making it available on their website and/or public databases, as they have already done with other genomes. Furthermore, Celera is not trying to patent genes. That's not where revenues come from presently, nor are they moving in that direction. And finally, Celera's future does not directly depend upon discovering cures or treatments. Again, that is not the source of their revenues, and it is not their mission. That will be largely the job of others, who will utilize Celera's enormous and unparalleled resources for a fee. The exception here may be Diversa, which developed out of TIGR, and in which Craig Venter holds a major stake. That might turn out to be a very interesting story indeed, particularly in light of the relationship between Venter, TIGR, HGSI, and DVSA: Message 13986939 Message 14023359 Regards, Walkingshadow